MK Cell Out-License & Lyramid SPA Update

AI SummaryClose X

Roquefort Therapeutics has agreed to out-license its MK Cell patents to Pleiades Pharma Ltd for up to US$25 million in milestone payments, plus a 1.5% royalty on net sales. Milestone payments include US$500,000 upon securing minimum fundraising, potentially increasing to US$650,000, and further payments triggered by regulatory submissions and approvals. Up to US$21 million is tied to achieving various worldwide sales targets. Additionally, the Longstop Date for the Lyramid sale to Pleiades has been extended to January 31, 2026, while the total consideration remains up to US$10.8 million. The selling party in the agreement has changed to Midkine Investments Ltd, and the third-party license agreement granting Lyramid rights to the Midkine antibody program will terminate on November 4, 2025.

Disclaimer*

UK 100

Latest directors dealings